[Featured Stock] 'Clinical Failure' Bridge Biotherapeutics Hits Lower Limit for Two Consecutive Days

Following the news of clinical failure of the core pipeline (new drug candidate), Bridge Biotherapeutics' stock price has hit the lower limit for two consecutive days.

As of 9:50 a.m. on the 16th, Bridge Biotherapeutics recorded 4,400 KRW, down 1,880 KRW (29.94%) from the previous trading day. The company also traded at 6,280 KRW the day before, down 2,680 KRW (29.91%) from the previous day.

Earlier, on the 14th, Bridge Biotherapeutics disclosed the topline data of the global Phase 2 clinical trial for the idiopathic pulmonary fibrosis (IPF) treatment candidate 'BBT-877,' stating that no significant improvement was observed in the primary endpoint, the change in forced vital capacity (FVC) at 24 weeks.

Bridge Biotherapeutics stated, "We plan to prioritize detailed analysis of the results for BBT-877's idiopathic pulmonary fibrosis indication through additional analysis," and added, "Since no particular issues were found in the safety profile, we will actively consider additional indications for BBT-877." They also mentioned, "We have other projects such as BBT-207 and BBT-301, so if necessary, we will reprioritize accordingly."

A representative from Bridge Biotherapeutics said, "The probability of a clinical trial drug ultimately receiving regulatory approval as a pharmaceutical product is statistically about 10%. During this process, results that do not meet expectations may occur, and accordingly, there is always a possibility of changing or abandoning commercialization plans," advising investors to carefully consider the disclosed investment risks comprehensively through timely disclosures and business reports before making investment decisions."